Market Overview

Deutsche Bank Maintains Buy Rating, $28 PT On AUXL


Deutsche Bank is tweaking its Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) 2011 revenue estimate from $268M to $269M but lowering its 2011 EPS estimate from $(0.56) to $(0.83), primarily on higher R&D and lower gross margins.

“We are also modestly lowering our 2012-14 revenue and EPS estimates, primarily on slightly lower Testim sales,” Deutsche Bank writes. “With a current market cap of $1.14B, the implied value for Xiaflex is approx $384M (ex-cash of $128M and applying a 3x rev multiple to our 2011 Testim est of $208M).

“We view this as increasingly attractive, given its potential applicability in a number of other unmet medical needs (e.g., Peyronies, cellulite, etc.).

“Rolling forward our valuation metrics, our 12-month PT remains $28, based on 24x our fully taxed 2013 EPS est of $1.33 (previously $1.57), discounted back 1 year at 15%. Key risks to our target include potential regulatory, reimbursement, or commercial setbacks for Xiaflex, as well as potential changes in the Testim growth outlook.”

Auxilium Pharmaceuticals closed Thursday at $22.24.

Posted-In: Auxilium Pharmaceuticals Deutsche BankAnalyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Piper Jaffray Leaves eBay Neutral Rating, $30 PT Unchanged (EBAY)

Piper Jaffray Raises PT On DaVita To $70